Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N2‑({[(4‑Bromophenyl)Methyl]Oxy}Carbonyl)‑N1‑[(1s)‑1-Formylpentyl]‑L-Leucinamide is a synthetic small molecule and a derivative of the amino acid leucine. It features a carbamate linkage to a 4-bromobenzene moiety and an amide bond to an N-formypentanyl group. The compound is classified as an amino acid, peptide, and analogue, specifically within the carboxylic acids and derivatives class. There are no approved medical indications or clinical trials for this molecule; it is considered experimental with no known therapeutic use or mechanism of action established in humans[2][3][5]. Its structure has been studied in protein-ligand complexes but there is no evidence of pharmaceutical development or commercial manufacturing.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N2-({[(4-Bromophenyl)Methyl]Oxy}Carbonyl)-N1-[(1s)-1-Formylpentyl]-L-Leucinamide.